HEPA News and Press, Hepion Pharmaceuticals Inc. From 11/30/20

Includes Full Exercise of Underwriters' Overallotment Option EDISON, NJ / ACCESSWIRE / November 30, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatm...

Gainers: AnPac Bio-Medical Science (ANPC) +97%.Mmtec (MTC) +79%.Newborn Acquisition (NBAC) +49%.Elys Game Technology (ELYS) +45%.WidePoint (WYY) +42%.ZK International (ZKIN) +39%.Cocrystal Pharma (COCP) +37%.Renalytix (RNLX) +31%.Tuniu (TOUR) +28%.Sierra Wireless (SWIR) +2...

Gainers: AnPac Bio-Medical Science (ANPC) +110%, Cocrystal Pharma (COCP) +56%, Renalytix AI (RNLX) +31%, Precigen (PGEN) +13%, Chiasma (CHMA) +11%.Losers: Hepion Pharmaceuticals (HEPA) -29%, Medigus (MDGS) -12%, Retractable Technologies (...

Hepion Pharmaceuticals (HEPA)-28% after prices equity offering at $1.50.Fuel Tech (FTEK) -25%.ECMOHO (MOHO) -24%.Ideanomics (IDEX) -17%.Nikola (NKLA) -15% on concerns over GM deal, gauntlet of stock.Blink Charging (BLNK) -12%.Li Auto (LI) -12%  Chinese EV stocks ...

Hepion Pharmaceuticals (HEPA) has priced its public offering of 20M common shares at $1.50/share, for expected gross proceeds of ~$30M. Underwriters' over-allotment is an additional 3M shares. Net proceeds will be used to fund R&D activities, for working capital and other general corporat...

EDISON, NJ / ACCESSWIRE / November 24, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced the pri...

Gainers: DPW Holdings (DPW) +179%.Ideanomics (IDEX) +65%.Fuel Tech (FTEK) +61%.Greenland Technologies (GTEC) +52%.Kaixin Auto (KXIN) +52%.FuelCell Energy (FCEL) +45%.CIIG Merger (CIIC) +37%.Graybug Vision (GRAY) +36%.Beam Global (BEEM) +35%.Marathon Patent (MARA) +33%.Losers: B...

- Interim DSMB review at the midpoint of the first dose cohort affirmed no safety or tolerability concerns with 75 mg of CRV431 in NASH patients - - DSMB recommended the AMBITION study continue with 225 mg CRV431 dose cohort - - Clinically significant reductions observed in the liv...

EDISON, NJ / ACCESSWIRE / November 17, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced tha...

EDISON, NJ / ACCESSWIRE / November 12, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced tha...